- |||||||||| rosomidnar liposomal (PNT2258) / GSK
Trial completion: PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) (clinicaltrials.gov) - Apr 22, 2020 P2, N=45, Completed, Despite demonstration of single-agent activity, ORR was lower than acceptable for further new therapy development. Active, not recruiting --> Completed
- |||||||||| rosomidnar liposomal (PNT2258) / GSK
Trial primary completion date: PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) (clinicaltrials.gov) - Feb 27, 2017 P2, N=61, Active, not recruiting, Trial primary completion date: Jul 2018 --> Sep 2016 Trial primary completion date: Jan 2017 --> Jul 2018
- |||||||||| rosomidnar liposomal (PNT2258) / GSK
Enrollment change, Trial termination, Trial primary completion date: PNT2258 for Treatment of Patients With Richter's Transformation (Brighton) (clinicaltrials.gov) - Jul 1, 2016 P2, N=5, Terminated, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Aug 2016 N=49 --> 5 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Jun 2016
- |||||||||| rosomidnar liposomal (PNT2258) / GSK
Trial primary completion date: PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) (clinicaltrials.gov) - Jun 23, 2016 P2, N=61, Active, not recruiting, N=49 --> 5 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Jun 2016 Trial primary completion date: Oct 2016 --> Jan 2017
- |||||||||| rosomidnar liposomal (PNT2258) / GSK
Trial initiation date, Trial primary completion date: PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine) (clinicaltrials.gov) - Nov 19, 2014 P2, N=62, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Oct 2014 --> Jan 2015 | Trial primary completion date: Apr 2016 --> Aug 2016
|